Ranbaxy Pharmaceuticals Canada Inc (RPCI), a wholly-owned subsidiary of Ranbaxy Laboratories Limited (RLL), has received an approval to manufacture and market RAN-Donepezil hydrochloride 5 mg and 10 mg tablets from Health Canada. The total market size of Aricept (Donepezil Hydrochloride) in Canada is $153.9 million ($CAD) and growing at 38 per cent (extended units). Donepezil hydrochloride is indicated in the treatment of dementia in Alzheimer’s patients.
“We are pleased to have gained approval for Donepezil Hydrochloride from Health Canada and are proud to announce a day one launch. The finished dosage form will be manufactured at Ohm Laboratories located in New Jersey, US and Ranbaxy anticipates this launch will be beneficial to patients and healthcare professionals, as well as a positive economic benefit to the healthcare system of Canada,” said Paul Drake, President, RPCI.
RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.
EP News Bureau – Mumbai